Tirzepatide denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Limits Tirzepatide Quantities — and Why You Can Appeal

Quantity-limit denials for tirzepatide from Cigna typically reflect the plan's effort to align dispensing to the FDA-approved titration schedule. The plan may restrict the number of pens, injections, or fills dispensed per period. These limits are not always calibrated to your prescriber's individualized titration plan, which creates a legitimate basis for appeal.

## Why This Denial Is Appealable

Cigna must apply its quantity limits consistently with the FDA-approved prescribing label. If your prescriber's prescribed quantity and titration schedule matches or is supported by that label, Cigna cannot simply override clinical judgment without justification. Additionally, if a lower-than-prescribed quantity creates a gap in therapy that poses clinical risk, that is a separate medical-necessity argument.

## Federal Appeal Framework

• Internal appeal: You have the right to a full internal appeal under ERISA §503 (employer plans) or applicable state law (individual/state plans). Submit within the deadline on your denial letter — typically 180 days.
• External review: If the internal appeal fails, ACA §2719 entitles most plan members to an independent external review by an accredited IRO. The external-review window is generally within approximately four months of exhausting internal remedies. Decisions are binding on the insurer.
• Expedited review: If a standard timeline would seriously jeopardize your health, request expedited review — decisions are typically required within 72 hours.

## Concrete Appeal Steps

1. Obtain the full denial letter and identify the exact quantity-limit policy Cigna applied. 2. Ask your prescriber to document in writing why the prescribed quantity and titration pace is medically necessary for your specific clinical situation. 3. Cross-reference the quantity against the FDA-approved prescribing label for tirzepatide — if the prescribed amount is within label, state that explicitly. 4. Submit your internal appeal with the documentation below. 5. If denied internally, file for external review immediately.

## Documentation to Gather

• Diagnosis confirmation: Chart notes confirming your diagnosis (obesity and/or type 2 diabetes as applicable), including relevant clinical severity indicators documented by your provider.
• Prescriber medical-necessity letter: A letter from your prescribing clinician explaining why the prescribed quantity is necessary, referencing the FDA label and any applicable guideline organization (e.g., relevant ADA or Obesity Medicine Association guidance).
• Prior treatment history: Dates and outcomes of any prior weight-management or diabetes therapies, showing why this agent and this titration plan are appropriate now.
• Titration schedule documentation: The specific titration plan your prescriber intends, demonstrating alignment with the FDA label.

## Criteria-Mapping Structure

For each requirement in Cigna's quantity-limit policy, create a two-column table: left column lists the plan's stated requirement exactly as written; right column cites the specific chart fact or prescriber attestation that satisfies it. Attach the FDA-approved prescribing label page that supports your prescribed quantity. This structure forces the reviewer to engage with each criterion individually rather than issuing a blanket denial.